Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cardiology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cardiology Other
    The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials - (BMJ)
    FDA Approves Dronedarone for Atrial Fibrillation or Atrial Flutter - (DGNews)
    Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease - (JAMA)
    Novel and conventional biomarkers for prediction of incident cardiovascular events in the community - (JAMA)
    Kidney function and risk of cardiovascular disease and mortality in women: a prospective cohort study - (BMJ)

    News archive

     Recent webcasts/CME - Cardiology Other
    • State of the Science in Managing the Treatment-Experienced Patient With HIV
    • What's New in Managing Treatment-Experienced Patients With HIV?
    • Applying Data to Practice: Case Vignettes
    • Rheumatoid Arthritis: The Heart of the Matter Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis
      Supraventricular Tachycardia in Children and Adolescents

      Webcasts/CME archive

       Recent cases - Cardiology Other
        Cardiogenic Shock Caused by Disulfiram
        Congenital Atresia of the Left Main Coronary Artery Associated With Patent Ductus Arteriosus and Aortic Regurgitation
        Pleural Effusion and Pulmonary Hypertension in a Patient With Parkinson Disease Treated With Cabergoline
        A Well-Circumscribed Density Along the Right Heart Border
        A Case of Massive Pulmonary Embolism with ST Elevation in Leads V1-4

        Cases archive
          




        my personal edition > cardiology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Statins Confer No Benefit for Treatment of Calcified Aortic Stenosis: Presented at AHA

        By Jill Stein

        DALLAS, TX -- November 14, 2005 -- Statin drugs appear to offer no benefit in terms of prevention of stenosis progression in patients with aortic stenosis, according to data presented here at the American Heart Association's (AHA) Scientific Sessions 2005.

        Todd Hitchcock, MD, Cardiology Fellow, Scripps Clinic/Green Hospital and The Scripps Research Institute, La Jolla, California, United States, reported the results on November 13th.

        His group examined the database of the Scripps Clinic echocardiography laboratory for patients with a diagnosis of aortic stenosis who had two echocardiograms at least 6 months apart.

        Dr. Hitchcock and colleagues gathered clinical and laboratory data on 61 statin-treated patients and 130 controls. Two investigators reviewed the echocardiograms independently for accuracy.

        Statin drugs are known to provide substantial benefits in patients with coronary artery disease, therefore, there is interest in whether these drugs may be effective for treating aortic stenosis, Dr. Hitchcock pointed out. Two prior studies with more than 200 patients found a significant decrease in the annualized rate of progression of aortic stenosis in statin-treated patients versus controls.

        In Dr. Hitchcock's study, the time between the two echocardiograms averaged 1.88 years in the control group and 2.08 years in the statin group (P = NS).

        Results showed no difference between statin-treated subjects and controls for annualized rate of progression measured by change in aortic valve area (-0.14 cm2/year versus -0.11 cm2/year) and change in mean gradient (4.8 mm Hg/year versus 3.6 mm Hg/year).

        Calcific aortic stenosis is the most common form of valvular heart disease in the industrialized world and is the leading indication for valve replacement in North America and Europe. Currently, no medical therapy is available to postpone its progression, and surgery is necessary with symptom onset.

        Severe aortic stenosis is present in 3% of persons over 75 years of age and almost 9% of those over 85.


        [Presentation title: A Retrospective Analysis Suggests No Benefit of Statins For Treatment of Calcific Aortic Stenosis. Abstract 1687]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send